{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:31:04Z","timestamp":1787632264982,"version":"build-2736575974"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,30]],"date-time":"2019-11-30T00:00:00Z","timestamp":1575072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,30]],"date-time":"2019-11-30T00:00:00Z","timestamp":1575072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12519-019-00320-9","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T10:57:20Z","timestamp":1575284240000},"page":"5-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Overview of Juvenile localized scleroderma and its management"],"prefix":"10.1007","volume":"16","author":[{"given":"Suzanne C.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8276-2866","authenticated-orcid":false,"given":"Rong-Jun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,30]]},"reference":[{"key":"320_CR1","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1111\/j.1468-3083.2012.04581.x","volume":"27","author":"F Succaria","year":"2013","unstructured":"Succaria F, Kurban M, Kibbi A, Abbas O. Clinicopathological study of 81 cases of localized and systemic scleroderma. J Eur Acad Dermatol Venereol. 2013;27:e191\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"320_CR2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/art.1780210404","volume":"21","author":"R Fleischmajer","year":"1978","unstructured":"Fleischmajer R, Gay S, Meigel WN, Perlish JS. Collagen in the cellular and fibrotic stages of scleroderma. Arthritis Rheum. 1978;21:418\u201328.","journal-title":"Arthritis Rheum"},{"key":"320_CR3","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00000372-199806000-00003","volume":"20","author":"J Torres","year":"1998","unstructured":"Torres J, S\u00e1nchez J. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol. 1998;20:242\u20135.","journal-title":"Am J Dermatopathol"},{"key":"320_CR4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/rheumatology\/kei251","volume":"45","author":"F Zulian","year":"2006","unstructured":"Zulian F, Athreya B, Laxer R, Nelson A, Feitosa de Oliveira S, Punaro M, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology. 2006;45:614\u201320.","journal-title":"Rheumatology"},{"key":"320_CR5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2008.05.005","volume":"59","author":"S Christen-Zaech","year":"2008","unstructured":"Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59:385\u201396.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archdermatol.2009.79","volume":"145","author":"J Leitenberger","year":"2009","unstructured":"Leitenberger J, Cayce R, Haley R, Adams-Huei B, Bergstresser P, Jacobe H. Distinct autoimmune syndromes in morphea. Arch Dermatol. 2009;145:545\u201350.","journal-title":"Arch Dermatol"},{"key":"320_CR7","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1002\/art.38814","volume":"66","author":"H Jacobe","year":"2014","unstructured":"Jacobe H, Ahn C, Arnett F, Reveille J. Major histocompatibility complex class i and class ii alleles may confer susceptibility to or protection against morphea. Arthritis Rheumatol. 2014;66:3170\u20137.","journal-title":"Arthritis Rheumatol"},{"key":"320_CR8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/acr2.1019","volume":"1","author":"E Wu","year":"2019","unstructured":"Wu E, Li S, Torok K, Virkud Y, Fuhlbrigge R, Rabinovich E, et al. Baseline description of the juvenile localized scleroderma subgroup from the childhood arthritis and rheumatology research alliance legacy registry. ACR Open Rheumatol. 2019;1:119\u201324.","journal-title":"ACR Open Rheumatol"},{"key":"320_CR9","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.3389\/fimmu.2019.01487","volume":"10","author":"S Khatri","year":"2019","unstructured":"Khatri S, Torok KS, Mirizio E, Liu C, Astakhova K. Autoantibodies in morphea: an update. Front Immunol. 2019;10:1487.","journal-title":"Front Immunol"},{"key":"320_CR10","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/art.21264","volume":"52","author":"F Zulian","year":"2005","unstructured":"Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52:2873\u201381.","journal-title":"Arthritis Rheum"},{"key":"320_CR11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fimmu.2019.00908","volume":"10","author":"KS Torok","year":"2019","unstructured":"Torok KS, Li SC, Jacobe HM, Taber SF, Stevens AM, Zulian F, et al. Immunopathogenesis of pediatric localized scleroderma. Front Immunol. 2019;10:908.","journal-title":"Front Immunol"},{"key":"320_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjd.15001","volume":"177","author":"AM Saracino","year":"2017","unstructured":"Saracino AM, Denton CP, Orteu CH. The molecular pathogenesis of morphoea: from genetics to future treatment targets. Br J Dermatol. 2017;177:34\u201346.","journal-title":"Br J Dermatol"},{"key":"320_CR13","doi-asserted-by":"crossref","first-page":"R188","DOI":"10.1186\/ar4378","volume":"15","author":"K Magee","year":"2013","unstructured":"Magee K, Kelsey C, Kurzinski K, Ho J, Mlakar L, Feghali-Bostwick C, et al. Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis Res Ther. 2013;15:R188.","journal-title":"Arthritis Res Ther"},{"key":"320_CR14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.semarthrit.2015.06.006","volume":"45","author":"K Torok","year":"2015","unstructured":"Torok K, Kurzinski K, Kelsey C, Yabes J, Magee K, Vallejo A, et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokines profiles. Semin Arthritis Rheum. 2015;45:284\u201393.","journal-title":"Semin Arthritis Rheum"},{"key":"320_CR15","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jid.2017.04.008","volume":"137","author":"J O\u2019Brien","year":"2017","unstructured":"O\u2019Brien J, Rainwater Y, Malviya N, Cyrus N, Auer-Hackenberg L, Hynan L, et al. Transcriptional and cytokine profiles identify cxcl9 as a biomarker of disease activity in morphe. J Invest Dermatol. 2017;137:1663\u201370.","journal-title":"J Invest Dermatol"},{"key":"320_CR16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaut.2019.04.008","volume":"10","author":"J Mertens","year":"2019","unstructured":"Mertens J, de Jong E, van den Hoogen L, Wienke J, Thurlings R, Seyger M, et al. The identification of ccl18 as biomarker of disease activity in localized scleroderma. J Autoimmun. 2019;10:86\u201393.","journal-title":"J Autoimmun"},{"key":"320_CR17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-019-1015-7","volume":"14","author":"C Magro","year":"2019","unstructured":"Magro C, Halteh P, Olson L, Kister I, Shapiro L. Linear scleroderma \u201cen coup de sabre\u201d with extensive brain involvement\u2014clinicopathologic correlations and response to anti-interleukin-6 therapy. Orphanet J Rare Dis. 2019;14:110.","journal-title":"Orphanet J Rare Dis"},{"key":"320_CR18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jaad.2014.04.009","volume":"71","author":"D Grabell","year":"2014","unstructured":"Grabell D, Hsieh C, Andrew R, Martires K, Kim A, Vasquez R, et al. The role of skin trauma in the distribution of morphea lesions: a cross-sectional survey of the morphea in adults and children cohort iv. J Am Acad Dermatol. 2014;71:493\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR19","doi-asserted-by":"crossref","unstructured":"Li S, Torok K, Rabinovich CE, Dedeoglu F, Ferguson PJ, Hong SD, et al. Initial results from a pilot comparative effectiveness study of three methotrexate-based consensus treatment plans for juvenile localized scleroderma. J Rheumatol. 2019 (in press).","DOI":"10.3899\/jrheum.190311"},{"key":"320_CR20","first-page":"171","volume":"13","author":"AV Marzano","year":"2003","unstructured":"Marzano AV, Menni S, Parodi A, Borghi A, Fuligni A, Fabbri P, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003;13:171\u20136.","journal-title":"Eur J Dermatol"},{"key":"320_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaad.2006.10.959","volume":"56","author":"M Tollefson","year":"2007","unstructured":"Tollefson M, Witman P. En coup de sabre morphea and Parry\u2013Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007;56:257\u201363.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/pde.13336","volume":"35","author":"JJ Schoch","year":"2018","unstructured":"Schoch JJ, Schoch BS, Werthel JD, McIntosh AL, Davis DMR. Orthopedic complications of linear morphea: implications for early interdisciplinary care. Pediatr Dermatol. 2018;35:43\u20136.","journal-title":"Pediatr Dermatol."},{"key":"320_CR23","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1365-2133.2011.10600.x","volume":"165","author":"L Weibel","year":"2011","unstructured":"Weibel L, Laguda B, Atherton D, Harper JI. Misdiagnosis and delay in referral of children with localized scleroderma. Br J Dermatol. 2011;165:1308\u201313.","journal-title":"Br J Dermatol"},{"key":"320_CR24","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/bjd.12606","volume":"169","author":"M Piram","year":"2013","unstructured":"Piram M, McCuaig CC, Saint-Cyr C, Marcoux D, Hatami A, Haddad E, et al. Short- and long-term outcome of linear morphoea in children. Br J Dermatol. 2013;169:1265\u201371.","journal-title":"Br J Dermatol"},{"key":"320_CR25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/acr.20070","volume":"62","author":"A Herrick","year":"2010","unstructured":"Herrick A, Ennis H, Bhushan M, Silman A, Baildam E. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res. 2010;62:213\u20138.","journal-title":"Arthritis Care Res"},{"key":"320_CR26","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/rheumatology\/ker521","volume":"51","author":"DP Hawley","year":"2012","unstructured":"Hawley DP, Baildam EM, Amin TS, Cruikshank MK, Davidson JE, Dixon J, et al. Access to care for children and young people diagnosed with localized scleroderma or juvenile SSC in the UK. Rheumatology (Oxford). 2012;51:1235\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"320_CR27","first-page":"73","volume":"24","author":"L Peterson","year":"1997","unstructured":"Peterson L, Nelson A, Su W, Mason T, O\u2019Fallon W, Gabriel S. The epidemiology of morphea (localized scleroderma) in Olmstead county 1960\u20131993. J Rheumatol. 1997;24:73\u201380.","journal-title":"J Rheumatol"},{"key":"320_CR28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.pcl.2018.04.002","volume":"65","author":"SC Li","year":"2018","unstructured":"Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatr Clin North Am. 2018;65:757\u201381.","journal-title":"Pediatr Clin North Am"},{"key":"320_CR29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clindermatol.2018.04.005","volume":"36","author":"S Florez-Pollack","year":"2018","unstructured":"Florez-Pollack S, Kunzler E, Jacobe HT. Morphea: current concepts. Clin Dermatol. 2018;36:475\u201386.","journal-title":"Clin Dermatol"},{"key":"320_CR30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","volume":"18","author":"RM Laxer","year":"2006","unstructured":"Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18:606\u201313.","journal-title":"Curr Opin Rheumatol"},{"key":"320_CR31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2133.2008.08647.x","volume":"159","author":"L Weibel","year":"2008","unstructured":"Weibel L, Harper JI. Linear morphoea follows Blaschko\u2019s lines. Br J Dermatol. 2008;159:175\u201381.","journal-title":"Br J Dermatol"},{"key":"320_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000413469","volume":"17","author":"R Happle","year":"1987","unstructured":"Happle R. The lines of Blaschko: a developmental pattern visualizing functional X-chromosome mosaicism. Curr Probl Derm. 1987;17:5\u201318.","journal-title":"Curr Probl Derm"},{"key":"320_CR33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archderm.1980.01640260045011","volume":"116","author":"JL Diaz-Perez","year":"1980","unstructured":"Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch Dermatol. 1980;116:169\u201373.","journal-title":"Arch Dermatol"},{"key":"320_CR34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/1534734607308731","volume":"6","author":"U Wollina","year":"2007","unstructured":"Wollina U, Buslau M, Heinig B, Petrov I, Unger E, Kyriopoulou E, et al. Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma. Int J Low Extrem Wounds. 2007;6:291\u20138.","journal-title":"Int J Low Extrem Wounds"},{"key":"320_CR35","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00296-019-04269-w","volume":"39","author":"HJ Soh","year":"2019","unstructured":"Soh HJ, Samuel C, Heaton V, Renton WD, Cox A, Munro J. Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review. Rheumatol Int. 2019;39:933\u201341.","journal-title":"Rheumatol Int"},{"key":"320_CR36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13023-015-0250-9","volume":"10","author":"S Tokachjiov","year":"2015","unstructured":"Tokachjiov S, Patel N, Tollefson M. Progressive hemifacial atrophy: a review. Orphanet J Rare Dis. 2015;10:39.","journal-title":"Orphanet J Rare Dis"},{"key":"320_CR37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00234-014-1448-6","volume":"57","author":"D Doolittle","year":"2015","unstructured":"Doolittle D, Lehman V, Schwartz K, Wong-Kisiel L, Lehman J, Tollefson M. CNS imaging findings associated with Parry\u2013Romberg syndrome and en coup de sabre: correlation to dermatologic and neurologic abnormalities. Neuroradiology. 2015;57:21\u201334.","journal-title":"Neuroradiology"},{"key":"320_CR38","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00431-015-2532-6","volume":"174","author":"L De Somer","year":"2015","unstructured":"De Somer L, Morren MA, Muller PC, Despontin K, Jansen K, Lagae L, et al. Overlap between linear scleroderma, progressive facial hemiatrophy and immune-inflammatory encephalitis in a paediatric cohort. Eur J Pediatr. 2015;174:1247\u201354.","journal-title":"Eur J Pediatr"},{"key":"320_CR39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/pde.12001","volume":"29","author":"YE Chiu","year":"2012","unstructured":"Chiu YE, Vora S, Kwon EK, Maheshwari M. A significant proportion of children with morphea en coup de sabre and Parry\u2013Romberg syndrome have neuroimaging findings. Pediatr Dermatol. 2012;29:738\u201348.","journal-title":"Pediatr Dermatol"},{"key":"320_CR40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2340\/00015555-2920","volume":"98","author":"A Kreuter","year":"2018","unstructured":"Kreuter A, Mitrakos G, Hofmann SC, Lehmann P, Sticherling M, Krieg T, et al. Localized scleroderma of the head and face area: a retrospective cross-sectional study of 96 patients from 5 German tertiary referral centres. Acta Derm Venereol. 2018;98:603\u20135.","journal-title":"Acta Derm Venereol"},{"key":"320_CR41","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1212\/01.wnl.0000334474.88923.e3","volume":"71","author":"I Kister","year":"2008","unstructured":"Kister I, Inglese M, Laxer R, Herbert J. Neurologic manifestations of localized scleroderma. A case report and literature review. Neurology. 2008;71:1538\u201345.","journal-title":"Neurology"},{"key":"320_CR42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pjnns.2016.02.002","volume":"50","author":"E Klimiec","year":"2016","unstructured":"Klimiec E, Klimkowicz-Mrowiec A. Mild cognitive impairment as a single sign of brain hemiatrophy in patient with localized scleroderma and Parry\u2013Romberg syndrome. Neurol Neurochir Pol. 2016;50:215\u20138.","journal-title":"Neurol Neurochir Pol"},{"key":"320_CR43","first-page":"719685","volume":"2012","author":"TN Amaral","year":"2012","unstructured":"Amaral TN, Marques Neto JF, Lapa AT, Peres FA, Guirau CR, Appenzeller S. Neurologic involvement in scleroderma en coup de sabre. Autoimmune Dis. 2012;2012:719685.","journal-title":"Autoimmune Dis."},{"key":"320_CR44","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/bjo.2007.116038","volume":"91","author":"M Zannin","year":"2007","unstructured":"Zannin M, Martini G, Athreya B, Russo R, Higgins G, Vittadello F, et al. Ocular involvement in children with localised scleroderma: a multi-centre study. Br J Opthalmol. 2007;91:1311\u20134.","journal-title":"Br J Opthalmol"},{"key":"320_CR45","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.survophthal.2016.03.009","volume":"61","author":"F Bucher","year":"2016","unstructured":"Bucher F, Fricke J, Neugebauer A, Cursiefen C, Heindl LM. Ophthalmological manifestations of Parry\u2013Romberg syndrome. Surv Ophthalmol. 2016;61:693\u2013701.","journal-title":"Surv Ophthalmol"},{"key":"320_CR46","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaapos.2016.12.004","volume":"21","author":"E Lenassi","year":"2017","unstructured":"Lenassi E, Vassallo G, Kehdi E, Chieng AS, Ashworth JL. Craniofacial linear scleroderma associated with retinal telangiectasia and exudative retinal detachment. J AAPOS. 2017;21:251\u20134.","journal-title":"J AAPOS"},{"key":"320_CR47","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1440-1754.2012.02435.x","volume":"48","author":"S Trainito","year":"2012","unstructured":"Trainito S, Favero L, Martini G, Pedersen T, Favero V, Herlin T, et al. Odontostomatologic involvement in juvenile localised scleroderma of the face. J Paediatr Child Health. 2012;48:572\u20136.","journal-title":"J Paediatr Child Health"},{"key":"320_CR48","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/SCS.0b013e31820fe339","volume":"22","author":"KH You","year":"2011","unstructured":"You KH, Baik HS. Orthopedic and orthodontic treatment of Parry\u2013Romberg syndrome. J Craniofac Surg. 2011;22:970\u20133.","journal-title":"J Craniofac Surg"},{"key":"320_CR49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/2231-0770.154193","volume":"5","author":"NA Al-Aizari","year":"2015","unstructured":"Al-Aizari NA, Azzeghaiby SN, Al-Shamiri HM, Darwish S, Tarakji B. Oral manifestations of Parry\u2013Romberg syndrome: a review of literature. Avicenna J Med. 2015;5:25\u20138.","journal-title":"Avicenna J Med"},{"key":"320_CR50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40368-014-0148-6","volume":"16","author":"M H\u00f8rberg","year":"2015","unstructured":"H\u00f8rberg M, Lauesen S, Daugaard-Jensen J, Kjaer I. Linear scleroderma en coup de sabre including abnormal dental development. Eur Arch Paediatr Dent. 2015;16:227\u201331.","journal-title":"Eur Arch Paediatr Dent"},{"key":"320_CR51","doi-asserted-by":"crossref","first-page":"691314","DOI":"10.1155\/2012\/691314","volume":"2012","author":"CA Canas","year":"2012","unstructured":"Canas CA, Orozco JL, Paredes AC, Bonilla-Abadia F. Successful treatment of hemifacial myokymia and dystonia associated to linear scleroderma \u201cen coup de sabre\u201d with repeated botox injections. Case Rep Med. 2012;2012:691314.","journal-title":"Case Rep Med"},{"key":"320_CR52","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","volume":"78","author":"F Zulian","year":"2019","unstructured":"Zulian F, Culpo R, Sperotto F, Anton J, Avcin T, Baildam EM, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis. 2019;78:1019\u201324.","journal-title":"Ann Rheum Dis"},{"key":"320_CR53","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/rheumatology\/ker142","volume":"50","author":"A Herrick","year":"2011","unstructured":"Herrick A, Ennis H, Bhushan M, Silman A, Baildam E. Clinical features of childhood localized scleroderma in an incidence cohort. Rheumatol. 2011;50:1865\u20138.","journal-title":"Rheumatol"},{"key":"320_CR54","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.1780390624","volume":"39","author":"R Vancheeswaran","year":"1996","unstructured":"Vancheeswaran R, Black C, David J, Hasson N, Harper JI, Atherton D, et al. Childhood-onset scleroderma. Arthritis Rheum. 1996;39:1041\u20139.","journal-title":"Arthritis Rheum"},{"key":"320_CR55","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.3899\/jrheum.080098","volume":"35","author":"T Arkachaisri","year":"2008","unstructured":"Arkachaisri T, Fertig N, Pino S, Medsger T Jr. Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study. J Rheumatol. 2008;35:2439\u201344.","journal-title":"J Rheumatol"},{"key":"320_CR56","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jpeds.2004.10.026","volume":"146","author":"S Sathornsumetee","year":"2005","unstructured":"Sathornsumetee S, Schanberg L, Rabinovich E, Lewis D Jr, Weisleder P. Parry\u2013Romberg syndrome with fatal brain stem involvement. J Pediatr. 2005;146:429\u201331.","journal-title":"J Pediatr"},{"key":"320_CR57","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3899\/jrheum.171381","volume":"45","author":"SC Li","year":"2018","unstructured":"Li SC, Li X, Pope E, Stewart K, Higgins GC, Rabinovich CE, et al. New features for measuring disease activity in pediatric localized scleroderma. J Rheumatol. 2018;45:1680\u20138.","journal-title":"J Rheumatol"},{"key":"320_CR58","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.3899\/jrheum.081284","volume":"36","author":"T Arkachaisri","year":"2009","unstructured":"Arkachaisri T, Vilaiyuk S, Li S, O\u2019Neil KM, Pope E, Higgins GC, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol. 2009;36:2819\u201329.","journal-title":"J Rheumatol"},{"key":"320_CR59","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/rheumatology\/kep361","volume":"49","author":"T Arkachaisri","year":"2010","unstructured":"Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA Jr. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford). 2010;49:373\u201381.","journal-title":"Rheumatology (Oxford)"},{"key":"320_CR60","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jaad.2013.02.007","volume":"69","author":"CE Kelsey","year":"2013","unstructured":"Kelsey CE, Torok KS. The localized scleroderma cutaneous assessment tool: responsiveness to change in a pediatric clinical population. J Am Acad Dermatol. 2013;69:214\u201320.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR61","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3899\/jrheum.110210","volume":"39","author":"KS Torok","year":"2012","unstructured":"Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol. 2012;39:286\u201394.","journal-title":"J Rheumatol"},{"key":"320_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18097","author":"NM Teske","year":"2019","unstructured":"Teske NM, Jacobe HT. Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify clinically significant change. Br J Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.18097.","journal-title":"Br J Dermatol."},{"key":"320_CR63","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.21687","volume":"64","author":"SC Li","year":"2012","unstructured":"Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2012;64:1175\u201385.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"320_CR64","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","volume":"63","author":"F Zulian","year":"2011","unstructured":"Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63:1998\u20132006.","journal-title":"Arthritis Rheum"},{"key":"320_CR65","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/41.10.1178","volume":"41","author":"G Martini","year":"2002","unstructured":"Martini G, Murray K, Howell KJ, Harper J, Atherton D, Woo P, et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatol. 2002;41:1178\u201382.","journal-title":"Rheumatol"},{"key":"320_CR66","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1148\/radiol.11102136","volume":"260","author":"S Schanz","year":"2011","unstructured":"Schanz S, Fierlbeck G, Ulmer A, Schmatzing M, K\u00fcmme\u00fcrle-Deschner J, Claussen C, et al. Localized scleroderma: MR findings and clinical features. Radiology. 2011;260:817\u201324.","journal-title":"Radiology"},{"key":"320_CR67","doi-asserted-by":"crossref","first-page":"W376","DOI":"10.2214\/AJR.12.9335","volume":"200","author":"S Schanz","year":"2013","unstructured":"Schanz S, Henes J, Ulmer A, Kotter I, Fierlbeck G, Claussen CD, et al. Response evaluation of musculoskeletal involvement in patients with deep morphea treated with methotrexate and prednisolone: a combined MRI and clinical approach. AJR Am J Roentgenol. 2013;200:W376\u201382.","journal-title":"AJR Am J Roentgenol"},{"key":"320_CR68","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s00247-018-4177-x","volume":"48","author":"E Maloney","year":"2018","unstructured":"Maloney E, Menashe SJ, Iyer RS, Ringold S, Chakraborty AK, Ishak GE. The central nervous system manifestations of localized craniofacial scleroderma: a study of 10 cases and literature review. Pediatr Radiol. 2018;48:1642\u201354.","journal-title":"Pediatr Radiol"},{"key":"320_CR69","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00431-018-3144-8","volume":"177","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari\u00a0I, Pain C, P\u00e1link\u00e1s A, H\u00f6ger P, Moll M, et al. Development of minimum standards of care for juvenile localized scleroderma. Eur J Pediatr. 2018;177:961\u201377.","journal-title":"Eur J Pediatr"},{"key":"320_CR70","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.autrev.2013.05.005","volume":"12","author":"MF Careta","year":"2013","unstructured":"Careta MF, Leite Cda C, Cresta F, Albino J, Tsunami M, Romiti R. Prospective study to evaluate the clinical and radiological outcome of patients with scleroderma of the face. Autoimmun Rev. 2013;12:1064\u20139.","journal-title":"Autoimmun Rev"},{"key":"320_CR71","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archderm.141.7.847","volume":"141","author":"A Kreuter","year":"2005","unstructured":"Kreuter A, Gambichler T, Breuckmann F, Rotterdam S, Freitag M, Stuecker M, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol. 2005;141:847\u201352.","journal-title":"Arch Dermatol"},{"key":"320_CR72","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11926-009-0028-y","volume":"11","author":"S Li","year":"2009","unstructured":"Li S, Liebling MS. The use of doppler ultrasound to evaluate lesions of localized scleroderma. Curr Rheumatol Rep. 2009;11:205\u201311.","journal-title":"Curr Rheumatol Rep"},{"key":"320_CR73","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/acr.20407","volume":"63","author":"SC Li","year":"2011","unstructured":"Li SC, Liebling MS, Haines KA, Weiss JE, Prann A. Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2011;63:735\u201342.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"320_CR74","first-page":"3","volume":"164","author":"K Hoffman","year":"1991","unstructured":"Hoffman K, Gerbaulet U, el-Gammal S,\u00a0Altmeyer P.\u00a020-MHz B-mode ultrasound in monitoring the course of localized scleroderma (morphea). Acta Derm Venereol (Stockh). 1991;164:3\u201316.","journal-title":"Acta Derm Venereol (Stockh)"},{"key":"320_CR75","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jaad.2010.08.027","volume":"65","author":"X Wortsman","year":"2011","unstructured":"Wortsman X, Wortsman J, Sazunic I, Carreno L. Activity assessment in morphea using color doppler ultrasound. J Am Acad Dermatol. 2011;65:942\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR76","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/archdermatol.2011.243","volume":"147","author":"K Nezafati","year":"2011","unstructured":"Nezafati K, Cayce R, Susa J, Setiawan A, Tirkes T, Bendeck S, et al. 14-MHz ultrasonography as an outcome measure in morphea (localized scleroderma). Arch Dermatol. 2011;147:1112\u20135.","journal-title":"Arch Dermatol"},{"key":"320_CR77","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/rheumatology\/kem120","volume":"46","author":"SC Li","year":"2007","unstructured":"Li SC, Liebling MS, Haines KA. Ultrasonography is a sensitive tool for monitoring localized scleroderma. Rheumatology. 2007;46:1316\u20139.","journal-title":"Rheumatology"},{"key":"320_CR78","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.autrev.2018.02.004","volume":"17","author":"G Martini","year":"2018","unstructured":"Martini\u00a0G, Fadanelli G, Agazzi A, Vittadello F, Meneghel A, Zulian F. Disease course and long-term outcome of juvenile localized scleroderma: experience from a single pediatric rheumatology centre and literature review. Autoimmun Rev. 2018;17:727\u201334.","journal-title":"Autoimmun Rev"},{"key":"320_CR79","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3899\/jrheum.090708","volume":"37","author":"SC Li","year":"2010","unstructured":"Li SC, Feldman BM, Higgins GC, Haines KA, Punaro MG, O\u2019Neil KM. Treatment of pediatric localized scleroderma: results of a survey of north american pediatric rheumatologists. J Rheumatol. 2010;37:175\u201381.","journal-title":"J Rheumatol"},{"key":"320_CR80","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/rheumatology\/keu212","volume":"53","author":"DP Hawley","year":"2014","unstructured":"Hawley DP, Pain CE, Baildam EM, Murphy R, Taylor AE, Foster HE. United kingdom survey of current management of juvenile localized scleroderma. Rheumatology (Oxford). 2014;53:1849\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"320_CR81","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/ddg.12724","volume":"14","author":"A Kreuter","year":"2016","unstructured":"Kreuter A, Krieg T, Worm M, Wenzel J, Moinzadeh P, Kuhn A, et al. German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges. 2016;14:199\u2013216.","journal-title":"J Dtsch Dermatol Ges"},{"key":"320_CR82","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jdv.14458","volume":"31","author":"R Knobler","year":"2017","unstructured":"Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol. 2017;31:1401\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"320_CR83","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1365-2133.2008.09017.x","volume":"160","author":"E Kroft","year":"2009","unstructured":"Kroft E, Creemers M, van den Hoogen F, Boezeman J, de Jong E. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol. 2009;160:1075\u201382.","journal-title":"Br J Dermatol"},{"key":"320_CR84","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamadermatol.2016.2873","volume":"152","author":"JS Mertens","year":"2016","unstructured":"Mertens JS, Zweers MC, Kievit W, Knaapen HK, Gerritsen M, Radstake TR, et al. High-dose intravenous pulse methotrexate in patients with eosinophilic fasciitis. JAMA Dermatol. 2016;152:1262\u20135.","journal-title":"JAMA Dermatol"},{"key":"320_CR85","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1365-2133.2006.07497.x","volume":"155","author":"L Weibel","year":"2006","unstructured":"Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol. 2006;155:1013\u201320.","journal-title":"Br J Dermatol"},{"key":"320_CR86","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-3476(00)90056-8","volume":"136","author":"Y Uziel","year":"2000","unstructured":"Uziel Y, Feldman B, Krafchik B, Yeung R, Laxer R. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr. 2000;136:91\u20135.","journal-title":"J Pediatr"},{"key":"320_CR87","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archderm.1994.01690050133027","volume":"130","author":"P Joly","year":"1994","unstructured":"Joly P, Bamberger N, Crickx B, Belaich S. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol. 1994;130:663\u20134.","journal-title":"Arch Dermatol"},{"key":"320_CR88","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12969-019-0350-5","volume":"17","author":"SC Li","year":"2019","unstructured":"Li SC, Fuhlbrigge RC, Laxer RM, Pope E, Ibarra MF, Stewart K, et al. Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the carra juvenile localized scleroderma consensus treatment plan pilot study. Pediatr Rheumatol Online J. 2019;17:43.","journal-title":"Pediatr Rheumatol Online J"},{"key":"320_CR89","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.17312","volume":"180","author":"KL Kurzinski","year":"2019","unstructured":"Kurzinski KL, Zigler CK, Torok KS. Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma. Br J Dermatol. 2019;180:1183\u20139.","journal-title":"Br J Dermatol"},{"key":"320_CR90","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2012.03.036","volume":"67","author":"F Zulian","year":"2012","unstructured":"Zulian F, Vallongo C, Patrizi A, Belloni-Fortina A, Cutrone M, Alessio M, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012;67:1151\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR91","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2133.2011.10535.x","volume":"166","author":"L Mirsky","year":"2012","unstructured":"Mirsky L, Chakkittakandiyil A, Laxer RM, O\u2019Brien C, Pope E. Relapse after systemic treatment in paediatric morphoea. Br J Dermatol. 2012;166:443\u20135.","journal-title":"Br J Dermatol"},{"key":"320_CR92","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/rheumatology\/kep244","volume":"48","author":"G Martini","year":"2009","unstructured":"Martini G, Ramanan A, Falcini F, Girschick H, Goldsmith D, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology. 2009;48:1410\u20133.","journal-title":"Rheumatology"},{"key":"320_CR93","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000448171","volume":"232","author":"G Bali","year":"2016","unstructured":"Bali G, Fruhauf J, Wutte N, Aberer E. Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review. Dermatology. 2016;232:503\u201310.","journal-title":"Dermatology"},{"key":"320_CR94","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/1346-8138.14801","volume":"46","author":"T Ogawa","year":"2019","unstructured":"Ogawa T, Okiyama N, Takamuki R, Inoue S, Saito A, Nakamura Y, et al. Juvenile case of multiple morphea profunda resulting in joint contracture that was successfully treated with cyclosporin a: a case report and review of the published works. J Dermatol. 2019;46:354\u20137.","journal-title":"J Dermatol"},{"key":"320_CR95","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jaad.2019.01.040","volume":"80","author":"AB Kumar","year":"2019","unstructured":"Kumar AB, Blixt EK, Drage LA, El-Azhary RA, Wetter DA. Treatment of morphea with hydroxychloroquine: a retrospective review of 84 patients at mayo clinic, 1996\u20132013. J Am Acad Dermatol. 2019;80:1658\u201363.","journal-title":"J Am Acad Dermatol."},{"key":"320_CR96","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/kex400","volume":"57","author":"H Lythgoe","year":"2018","unstructured":"Lythgoe H, Baildam E, Beresford M, Cleary G, McCann L, Pain C. Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology. 2018;57:401\u20132.","journal-title":"Rheumatology"},{"key":"320_CR97","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5301\/jsrd.5000259","volume":"2","author":"I Foeldvari","year":"2018","unstructured":"Foeldvari I, Anton J, Friswell M, Bica B, de Inocencio J, Aquilani A, et al. Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients. J Scleroderma Relat Disord. 2018;2:203\u20137.","journal-title":"J Scleroderma Relat Disord"},{"key":"320_CR98","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/18743129014090100030","volume":"9","author":"ID Ferguson","year":"2015","unstructured":"Ferguson ID, Weiser P, Torok KS. A case report of successful treatment of recalcitrant childhood localized scleroderma with infliximab and leflunomide. Open Rheumatol J. 2015;9:30\u20135.","journal-title":"Open Rheumatol J"},{"key":"320_CR99","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.semarthrit.2016.08.018","volume":"46","author":"F Adeeb","year":"2017","unstructured":"Adeeb F, Anjum S, Hodnett P, Kashif A, Brady M, Morrissey S, et al. Early- and late-stage morphea subtypes with deep tissue involvement is treatable with abatacept (orencia). Semin Arthritis Rheum. 2017;46:775\u201381.","journal-title":"Semin Arthritis Rheum"},{"key":"320_CR100","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2340\/00015555-1136","volume":"91","author":"B Stausb\u00f8l-Gr\u00f8n","year":"2011","unstructured":"Stausb\u00f8l-Gr\u00f8n B, Olesen A, Deleuran B, Deleuran M. Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases. Acta Derm Venereol. 2011;91:686\u20138.","journal-title":"Acta Derm Venereol"},{"key":"320_CR101","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2340\/00015555-2878","volume":"98","author":"SW Fage","year":"2018","unstructured":"Fage SW, Arvesen KB, Olesen AB. Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: a case series. Acta Derm Venereol. 2018;98:465\u20136.","journal-title":"Acta Derm Venereol"},{"key":"320_CR102","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","volume":"4","author":"SR Kim","year":"2018","unstructured":"Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the janus kinase inhibitor tofacitinib. JAAD Case Rep. 2018;4:443\u20135.","journal-title":"JAAD Case Rep"},{"key":"320_CR103","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1365-2133.1998.02060.x","volume":"138","author":"D Todd","year":"1998","unstructured":"Todd D, Askari A, Ektaish E. Puva therapy for disabling pansclerotic morphoea of children. Br J Dermatol. 1998;138:201\u20132.","journal-title":"Br J Dermatol"},{"key":"320_CR104","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2230.2004.01693.x","volume":"30","author":"RF Rose","year":"2005","unstructured":"Rose RF, Goodfield MJ. Combining puva therapy with systemic immunosuppression to treat progressive diffuse morphoea. Clin Exp Dermatol. 2005;30:226\u20138.","journal-title":"Clin Exp Dermatol"},{"key":"320_CR105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2009.159","volume":"5","author":"P Song","year":"2009","unstructured":"Song P, Gocke C, Wigley F, Boin F. Resolution of pansclerotic morphea after treatment with antithymocyte globulin. Nat Rev Rheumatol. 2009;5:513\u20136.","journal-title":"Nat Rev Rheumatol"},{"key":"320_CR106","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/1756-185X.12555","volume":"18","author":"V Nair","year":"2015","unstructured":"Nair V, Sharma A, Sharma S, Das S, Bhakuni DS, Narayanan K, et al. Successful autologous hematopoietic stem cell transplantation for a patient with rapidly progressive localized scleroderma. Int J Rheum Dis. 2015;18:366\u201371.","journal-title":"Int J Rheum Dis"},{"key":"320_CR107","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/acr.20099","volume":"62","author":"E Le","year":"2010","unstructured":"Le E, Freischlag J, Christo P, Chhabra A, Wigley F. Thoracic outlet syndrome secondary to localized scleroderma treated with botulinum toxin injection. Arthrits Care Res. 2010;62:430\u20133.","journal-title":"Arthrits Care Res"},{"key":"320_CR108","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/mdc3.12760","volume":"6","author":"DM Radhakrishnan","year":"2019","unstructured":"Radhakrishnan DM, Goyal V, Shukla G, Singh MB, Ramam M. Hemi masticatory spasm: series of 7 cases and review of literature. Mov Disord Clin Pract. 2019;6:316\u20139.","journal-title":"Mov Disord Clin Pract"},{"key":"320_CR109","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/DSS.0000000000000812","volume":"42","author":"L Rimoin","year":"2016","unstructured":"Rimoin L, Arbiser J. Improvement of \u201cen coup de sabre\u201d morphea and associated headaches with botulinum toxin injections. Dermatol Surg. 2016;42:1216\u20139.","journal-title":"Dermatol Surg"},{"key":"320_CR110","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s13075-014-0510-4","volume":"16","author":"M Rodr\u00edguez-Castellanos","year":"2015","unstructured":"Rodr\u00edguez-Castellanos M, Tlacuilo-Parra A, S\u00e1nchez-Enr\u00edquez S, V\u00e9lez-G\u00f3mez E, Guevara-Guti\u00e9rrez E. Pirfenidone gel in patients with localized scleroderma: a phase ii study. Arthritis Rheum Ther. 2015;16:510\u20134.","journal-title":"Arthritis Rheum Ther"},{"key":"320_CR111","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40257-017-0269-x","volume":"18","author":"JS Mertens","year":"2017","unstructured":"Mertens JS, Seyger MMB, Thurlings RM, Radstake TRDJ, de Jong EMGJ. Morphea and eosinophilic fasciitis: an update. Am J Clin Dermatol. 2017;18:491\u2013512.","journal-title":"Am J Clin Dermatol"},{"key":"320_CR112","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/CCID.S160923","volume":"11","author":"R Noakes","year":"2018","unstructured":"Noakes R. Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast. Clin Cosmet Investig Dermatol. 2018;11:321\u20136.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"320_CR113","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2010.09.006","volume":"65","author":"B Zwischenberger","year":"2011","unstructured":"Zwischenberger B, Jacobe H. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011;65:925\u201341.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR114","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.semarthrit.2018.03.003","volume":"48","author":"E Marrani","year":"2018","unstructured":"Marrani E, Foeldvari I, Lopez J, Cimaz R, Simonini G. Comparing ultraviolet light a photo(chemo)therapy with methotrexate protocol in childhood localized scleroderma: evidence from systematic review and meta-analysis approach. Semin Arthritis Rheum. 2018;48:495\u2013503.","journal-title":"Semin Arthritis Rheum"},{"key":"320_CR115","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7326\/0003-4819-104-6-849","volume":"104","author":"V Falanga","year":"1986","unstructured":"Falanga V, Medsger TA Jr, Reichlin M, Rodnan GP.\u00a0Linear scleroderma.\u00a0Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med. 1986;104:849\u201357.","journal-title":"Ann Intern Med"},{"key":"320_CR116","first-page":"4535804","volume":"2018","author":"K Mishima","year":"2018","unstructured":"Mishima K, Kitoh\u00a0H, Matsushita M, Nagata T, Kamiya Y, Ishiguro N. Extensive bone lengthening for a patient with linear morphea. Case Rep Orthop. 2018;2018:4535804.","journal-title":"Case Rep Orthop"},{"key":"320_CR117","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/archdermatol.2011.247","volume":"147","author":"D Kineston","year":"2011","unstructured":"Kineston D, Kwan J. Use of a fractional ablative 10.6-\u03bcm carbon dioxide laser in the treatment of a morphea-related contracture. Arch Dermatol. 2011;147:1148\u201350.","journal-title":"Arch Dermatol."},{"key":"320_CR118","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.3899\/jrheum.100062","volume":"37","author":"M Palmero","year":"2010","unstructured":"Palmero M, Uziel Y, Laxer R, Forrest C, Pope E. En coup de sabre scleroderma and Parry\u2013Romberg syndrome in adolescents: surgical options and patient-related outcomes. J Rheumatol. 2010;37:2174\u20139.","journal-title":"J Rheumatol"},{"key":"320_CR119","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1590\/abd1806-4841.20132115","volume":"88","author":"T Zanelato","year":"2013","unstructured":"Zanelato T, Marquesini G, Colpas P, Magalh\u00e3es R, de Moraes A. Implantation of autologous fat globules in localized scleroderma and idiopathic lipoatrophy\u2014report of five patients. An Bras Dermatol. 2013;88:120\u20133.","journal-title":"An Bras Dermatol"},{"key":"320_CR120","first-page":"131","volume":"31","author":"E Segna","year":"2017","unstructured":"Segna E, Pucciarelli V, Beltramini GA, Sforza C, Silvestre FJ, Gianni AB, et al. Parry Romberg syndrome and linear facial scleroderma: management in pediatric population. J Biol Regul Homeost Agents. 2017;31:131\u20138.","journal-title":"J Biol Regul Homeost Agents"},{"key":"320_CR121","doi-asserted-by":"crossref","first-page":"166","DOI":"10.7181\/acfs.2017.18.3.166","volume":"18","author":"JH Lee","year":"2017","unstructured":"Lee JH, Lim SY, Lee JH, Ahn HC. Surgical management of localized scleroderma. Arch Craniofac Surg. 2017;18:166\u201371.","journal-title":"Arch Craniofac Surg"},{"key":"320_CR122","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1590\/abd1806-4841.20163867","volume":"91","author":"JP Franco","year":"2016","unstructured":"Franco JP, Serra MS, Lima RB, D\u2019Acri AM, Martins CJ. Scleroderma en coup de sabre treated with polymethylmethacrylate\u2014case report. An Bras Dermatol. 2016;91:209\u201311.","journal-title":"An Bras Dermatol"},{"issue":"Suppl 113","key":"320_CR123","first-page":"183","volume":"36","author":"S Mura","year":"2018","unstructured":"Mura S, Fin A, Parodi PC, Denton CP, Howell KJ, Rampino Cordaro E. Autologous fat transfer in the successful treatment of upper limb linear morphoea. Clin Exp Rheumatol. 2018;36(Suppl 113):183.","journal-title":"Clin Exp Rheumatol"},{"key":"320_CR124","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/PRS.0000000000004386","volume":"141","author":"B Chen","year":"2018","unstructured":"Chen B, Wang X, Long X, Zhang M, Huang J, Yu N, et al. Supportive use of adipose-derived stem cells in cell-assisted lipotransfer for localized scleroderma. Plast Reconstr Surg. 2018;141:1395\u2013407.","journal-title":"Plast Reconstr Surg"},{"key":"320_CR125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2230.2012.04385.x","volume":"37","author":"J Furuzawa-Carballeda","year":"2012","unstructured":"Furuzawa-Carballeda J,\u00a0Ort\u00edz-\u00c1valos M,\u00a0Lima G,\u00a0Jurado-Santa Cruz F,\u00a0Llorente L. Subcutaneous administration of polymerized type i collagen downregulates interleukin (IL)-17a, IL-22 and transforming growth factor-\u03b21 expression, and increases Foxp3-expressing cells in localized scleroderma. Clin Exp Dermatol. 2012;37:599\u2013609.","journal-title":"Clin Exp Dermatol"},{"key":"320_CR126","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/1090820X13485409","volume":"33","author":"A Takeda","year":"2013","unstructured":"Takeda A, Akimoto M, Hayashi K, Kounoike N, Nemoto M, Uchinuma E. Surgical management of breast deformity in a young patient with localized scleroderma: a case report and literature review. Aesthet Surg J. 2013;33:691\u20137.","journal-title":"Aesthet Surg J"},{"key":"320_CR127","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2013.11.037","volume":"70","author":"S Das","year":"2014","unstructured":"Das S, Bernstein I, Jacobe H. Correlates of self-reported quality of life in adults and children with morphea. J Am Acad Dermatol. 2014;70:904\u201310.","journal-title":"J Am Acad Dermatol"},{"key":"320_CR128","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s11136-018-1897-1","volume":"27","author":"G Bali","year":"2018","unstructured":"Bali G, K\u00e1rp\u00e1ti S, S\u00e1rdy M, Brodszky V, Hidv\u00e9gi B, Rencz F. Association between quality of life and clinical characteristics in patients with morphea. Qual Life Res. 2018;27:2525\u201332.","journal-title":"Qual Life Res"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-019-00320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12519-019-00320-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-019-00320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T23:16:04Z","timestamp":1722122164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12519-019-00320-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,30]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1007\/s12519-019-00320-9","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,30]]},"assertion":[{"value":"21 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The original source of figures and photographs not supplied by the author are acknowledged, and permission was obtained for their use. Patients consented to the use of their photographs for scientific publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No financial or non-financial benefits have been received or will be received from any party related directed or indirectly to the subject of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}